PSMAfore: Radioligand Therapy in the Future of Prostate Cancer Treatment
Radioligands in the future of prostate cancer treatmentПодробнее
Lu-PSMA Radioligand TherapyПодробнее
Personalized Cancer Therapy: Using PSMA Radioligand Therapy of Metastatic Prostate CancerПодробнее
Recent Trials of Interest, Barriers to Radioligand Therapy, and Nuances in PSMA EngagementПодробнее
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPCПодробнее
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://img.youtube.com/vi/upLVFTNeq9o/0.jpg)
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PCПодробнее
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC](https://img.youtube.com/vi/BgbkDD3Orew/0.jpg)
ASCO 2024 highlights: the PSMAfore trial for patients with mCRPCПодробнее
Looking Ahead: What Does the Future Hold for Radioligand Therapy in Prostate Cancer?Подробнее
Chemotherapy and Radioligand Therapy for Advanced Prostate CancerПодробнее
PSMA Imaging: Place in Prostate Cancer Landscape and Trials Outpacing Clinical PracticeПодробнее
Lu-PSMA-617 deployment and future of prostate cancer treatmentПодробнее
Uromigos Live 2023: Current and Future Status of Radioligand Therapy in Prostate CancerПодробнее
Advances in PSMA radioligand therapy for mCRPCПодробнее
Radioligand therapy advancements in prostate cancerПодробнее
PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient ConferenceПодробнее
#UromigosLive24 Radioligands Part 1: VISION and PSMAFore DiscussionПодробнее
3 Future Prostate Cancer Treatment Advancements | Mark Scholz, MD & Mark Moyad, MD | 2021 PCRIПодробнее
Radiotherapy and AI in the future of prostate cancer treatmentПодробнее
Radioligands: Uromigos Live 2024Подробнее
